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Sensitisation to Ambrosia in Switzerland: a public health threat
on the wait
Abstract
BACKGROUND: Ambrosia artemisiifolia (short name = Ambrosia common ragweed) pollen is a potent
allergen and has recently been found in Switzerland, spreading from the southwest of the country. The
aim of this study is to describe Ambrosia sensitisation rates in the population-based SAPALDIA cohort
(Swiss Study on Air Pollution And Lung Diseases In Adults) and to test whether an increase in these
rates could be observed. METHODS: Among the 6345 participants from 8 areas who provided blood
samples in 1991 and 2002, 5823 had valid results for specific IgE against common inhalant allergens
tested with Phadiatop. In 2002 Ambrosia sensitisation was measured and positive tests were analysed
for Artemisia vulgaris (mugwort). Blood samples taken in 1991 in Ticino and Geneva were also tested
for Ambrosia. RESULTS: Sensitisation rate (Phadiatop) did not increase significantly between the two
surveys and sensitisation was found in 30% of the participants. A proportion of 7.9% showed specific
IgE to Ambrosia pollen. The sensitisation rate in Lugano and Geneva had not changed substantially
since 1991. Among those sensitised to Ambrosia 82% also showed specific IgE against Artemisia,
suggesting a high rate of cross-reactivity. Only 1.3% were sensitized to Ambrosia alone. The incidence
of asthma or hay fever in participants with specific IgE to Ambrosia pollen was not higher than in the
general study population. CONCLUSION: Currently Ambrosia pollen does not appear to be an
important cause of inhalant allergies in Switzerland. Sensitisation rates are low and have not increased
since 1991. Due to cross-reactivity Ambrosia sensitisation may be a consequence of primary
sensitisation to Artemisia. Elimination of Ambrosia plants is nevertheless mandatory to avoid a future
increase.
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Background: Ambrosia artemisiifolia (short
name = Ambrosia common ragweed) pollen is a
potent allergen and has recently been found in
Switzerland, spreading from the southwest of the
country. The aim of this study is to describe Am-
brosia sensitisation rates in the population-based
SAPALDIA cohort (Swiss Study on Air Pollution
And Lung Diseases In Adults) and to test whether
an increase in these rates could be observed.
Methods: Among the 6345 participants from 
8 areas who provided blood samples in 1991 and
2002, 5823 had valid results for specific IgE
against common inhalant allergens tested with
Phadiatop®. In 2002 Ambrosia sensitisation was
measured and positive tests were analysed for
Artemisia vulgaris (mugwort). Blood samples
taken in 1991 in Ticino and Geneva were also
tested for Ambrosia.
Results: Sensitisation rate (Phadiatop®) did
not increase significantly between the two surveys
and sensitisation was found in 30% of the partici-
pants. A proportion of 7.9% showed specific IgE
to Ambrosia pollen. The sensitisation rate in
Lugano and Geneva had not changed substan-
tially since 1991. Among those sensitised to Am-
brosia 82% also showed specific IgE against
Artemisia, suggesting a high rate of cross-reactiv-
ity. Only 1.3% were sensitized to Ambrosia alone.
The incidence of asthma or hay fever in partici-
pants with specific IgE to Ambrosia pollen was
not higher than in the general study population.
Conclusion: Currently Ambrosia pollen does
not appear to be an important cause of inhalant
allergies in Switzerland. Sensitisation rates are
low and have not increased since 1991. Due to
cross-reactivity Ambrosia sensitisation may be 
a consequence of primary sensitisation to
Artemisia. Elimination of Ambrosia plants is nev-
ertheless mandatory to avoid a future increase. 
Key words: allergy; Ambrosia; Artemisia; hay
fever; cross-reactivity; sensitisation
Summary
Ambrosia artemisiifolia (short name Ambrosia
or common ragweed) pollen may produce major
hay fever symptoms during its pollination period
in late summer and autumn. It has been accused
of being one of the strongest sensitising pollens
[1] in various countries [2]. In Switzerland, Am-
brosia has spread from the areas of Geneva and
Ticino in recent years and has been observed to a
minor extent in many regions [3, 4].  Concern has
therefore been expressed regarding potential sen-
sitisation to Ambrosia pollen in the population
and its possible increase in recent years [5]. 
SAPALDIA (Swiss Cohort Study on Air Pol-
lution and Lung Diseases in Adults) was initiated
in 1991 with the primary aim of investigating the
impact of air pollution on respiratory health [6].
The data collected also made it possible to study
allergic sensitisation rates in the Swiss population.
Several publications have described the preva-
lence of sensitisation to various respiratory aller-
gens and influencing factors in the Swiss popu -
lation [7–9] and in Europe [10, 11]. The same
subjects were invited for a second examination in
2002 [12, 13]. In view of the increase in Ambrosia
pollen it was decided in 2002 to specifically test
sensitisation to Ambrosia pollen in this study pop-
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ulation. Initially and in 2002, the participants
were tested with Phadiatop® (Phadia Uppsala
Sweden) which contains a mixture of common
respiratory allergens, including Artemisia vulgaris
(short name Artemisia or mugwort) which may
show cross-reactivity with Ambrosia [14]. A high
level of cross-reactivity between the allergens of
these two pollens has been demonstrated on a
molecular level analysing the three-dimensional
structure [1] and with very recently introduced
molecular array techniques [15]. However, co-
sensitisation, i.e., independent sensitisation to ei-
ther allergen, is possible [16] .
Highest pollen counts have been reported in
the southern part of Switzerland (Ticino) and in
the area of Geneva. While in Geneva an increase
in pollen load has been described since 1993 [3],
this trend was not observable in Ticino [17].
Long-distance transport of Ambrosia pollen from
France and Italy seems to play an important role
in Switzerland, but pollens are also produced lo-
cally [18]. Systematic monitoring has been intro-
duced in Ticino and Geneva [4].
Thus it was also decided to test the frozen
serum samples taken in 1991 from SAPALDIA
participants in Geneva and Lugano (Ticino) for
IgE to Ambrosia and Artemisia, and to compare
the longitudinal changes in these sensitisations in
two potentially exposed populations.
Methods 
The eight study areas (Geneva, Basel, Lugano,
Aarau, Wald, Payerne, Davos, Montana) were chosen to
represent the variety of environmental conditions in re-
spect of geography, climate, degree of urbanisation and
air pollution in Switzerland. From the local registries of
inhabitants of these areas random population samples of
persons aged 18–60 years, having resided in the respective
area for at least three years, were then drawn [6].
In 1991, blood samples were taken from the partici-
pants and serum samples were stored at –20 °C before
despatch to the laboratory for testing. Total serum IgE
was measured using the Pharmacia CAP FEIA system
and the presence of specific serum IgE antibodies to a
mixture of relevant respiratory allergens (pollen, house
dust mites, moulds and animal epithelia) was assessed by
the Phadiatop® test (Phadia Uppsala Sweden) [14]. Posi-
tive reaction was defined as proposed by the manufac-
turer. All serum testing for IgE was done in the Allergy
Laboratory of the Department of Dermatology, Univer-
sity Hospital Zurich in 1993. Blood samples of two volun-
teers (both consistently Phadiatop® positive) were used as
quality control. 
In 2002 blood samples were again taken from the
same individuals and stored at –80°. The same technicians
in the same laboratory analysed these samples with the
same methods between June 2005 and November 2007.
The analysis included total IgE and Phadiatop®. Am-
brosia was tested in all samples except from the ones of
the two alpine regions of Davos and Montana (in which
Ambrosia had not been observed) and Artemisia was
tested if there was a positive result to Ambrosia. For both
allergens the commercial assay (Immuno CAP Pharma-
cia) was used. 
The results are reported as absolute and relative fre-
quencies (or percentages). Exact 95% confidence inter-
vals of proportions were computed. Changes in preva-
lence were assessed using the McNemar test and confi-
dence intervals of these changes were computed based on
the proportion of converters from – to + among all con-
verters, while the number of converters was assumed to
be fixed. All tests were two-tailed at a significance level of
0.05. Statistical analyses were done using SAS Version
9.1.
Results
Table 1 shows the total number of subjects
whose serum could be analysed in the cohort in
1991 and 2002 for the different areas. A total of
5823 persons provided interpretable results in
both instances. Of these, 4774 subjects had Am-
brosia measurements in 2002, and 375 of them
showed a positive test result. Artemisia was tested
in 327 of these subjects. In addition, 1093 old sera
(i.e., from 1991) of participants from Lugano and
Geneva were also tested for Ambrosia. 111 of
these sera were positive and 108 of them were ad-
ditionally tested for Artemisia. 
Sensitisation to respiratory allergens
Figure 1 shows that in most places the pro-
portion with a positive reaction to some respira-
tory allergen(s) contained in Phadiatop® remained
remarkably similar between the two surveys.
Overall, the sensitisation rate increased from
29.3% in 1991 to 30.3% in 2002 (p = 0.015, 95%-
CI of change = [0.2–1.9%]). In Basel the sensitisa-
tion rate increased from 34.7 to 37.5% (p = 0.013,
95%-CI of change = [0.6% to 4.8%]). The pro-
portion with positive reactions in both instances
varied between 31% (Basel) and 18% (Payerne),
whereas the number of converters from positive
to negative was largest in Geneva and of convert-
ers from negative to positive in Lugano. There
was no clear change in reactivity to respiratory al-
lergens over this period of time; however, between
3 and 6% of the population lost their sensitisation,
while between 5 and 7% newly tested positive to
Phadiatop®. New positivity was mainly found in
younger age groups, whereas decline in reactivity
was more frequent in older subjects; thus the tran-
sition probabilities from positive to negative are
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high in older persons, whereas the younger age
groups have a greater probability of becoming
newly sensitised to inhalant allergens (table 2).
Ambrosia sensitisation
Table 3 shows that between 6% (Payerne) and
10% (Basel) of the population are sensitised to
Ambrosia. The proportion of those sensitised to
Ambrosia but not to Artemisia varies between 
1 and 2%, with Basel also having the highest
 positivity rate for Ambrosia (2.1%) in this analy-
sis. As Ambrosia was still rare in Switzerland in
1991 it is particularly interesting to examine the
evolution between 1991 and 2002.
Evolution of Ambrosia sensitisation
In view of the longer presence and higher
pollen load of Ambrosia in Geneva and Lugano
(Ticino) as compared to other areas of Switzer-
land, we used the cohorts of these two areas to
test whether an increase in Ambrosia sensitisation
could be observed. Data from 1091 subjects could
be used for this purpose (see table 1) and 1082 in-
dividuals also provided valid results for Artemisia.
Table 4 shows the evolution between the two
examinations in the populations from Geneva and
Lugano (Ticino). Subjects with sensitisation to
Ambrosia but not Artemisia (i.e., who must be
specifically sensitised to Ambrosia) made up 1.1%
of the population in 2002 and 1.9% in 1991. A
new positivity to Ambrosia alone was observed
only in 3 individuals (0.3%) and new sensitisation
to Ambrosia and Artemisia in 1.1%. Thus a maxi-
mum of 14 persons (1.4%), might have been
newly sensitised to Ambrosia in 11 years. At the
same time 44 (4.0%) persons who tested positive
to one of the two allergens in 1991 where no
longer sensitised in 2002. This development did
not show any significant differences between the
two areas (data not shown).
Symptom development in persons with posi-
tive Phadiatop® and/or Ambrosia reactions
To determine whether Ambrosia sensitised per-
sons have a higher probability of developing
asthma or hay fever, we compared the incidence
of these two conditions across the four subgroups
with distinct patterns of sensitisation to Phadia -
top® and Ambrosia (i.e., +/+, +/–, –/+ and –/–) in
persons from Lugano and Geneva who did not
have physician-diagnosed asthma in 1991 (N =
Participants with Phadiatop® Ambrosia Ambrosia measured Artemisia
blood samples measurement measurements (2002) in both surveys measurements*
Basel 806 778 778 nm** 74 (698)
Wald 1178 1097 1095 nm 62 (1010)
Davos 513 460 3 nm nm
Lugano 870 743 741 698 1991:65 (480)
2002:48 (689)
Montana 610 587 nm nm nm
Payerne 856 811 810 nm 40 (761)
Aarau 981 949 949 nm 74 (870)
Geneva 531 398 398 393 1991:43 (251)
2002: 29 (365)
Total all areas 6345 5823 4774 1091 1991: 108 (731)
2002: 327 (4393)
* Artemisia was tested in Ambrosia-sensitive subjects only. In parentheses: number of subjects categorised as “non-sensitised 
to Artemisia” based on their negative Phadiatop test result
** nm = not measured
Table 1
Number of samples
tested by study area
with valid results.
Figure 1
Rates of sensitisation to Phadiatop® in the two surveys (1991 and 2002). Yellow
 segments: Phadiatop® positive in both surveys; green segments: converters from 
positive to negative; red segments: converters from negative to positive.
1991 2002 1991 2002 1991 2002 1991 2002 1991 2002 1991 2002 1991 2002
Geneva Basel Lugano Aarau Payerne Wald overall
%
40
35
30
25
20
15
10
5
0
Age category Probability of newly aquired Probability of lost Phadiatop®
SAPALDIA (1991) Phadiatop® positivity*a positivity**a
<30 0.107 0.111
(0.084–0.133) (0.083–0.144)
30–40 0.090 0.126
(0.073–0.110) (0.097–0.160)
40–50 0.074 0.175
(0.061–0.090) (0.141–0.213)
>50 0.057 0.222
(0.044–0.072) (0.180–0.269) 
trend test p <0.0001 p <0.0001
* Among subjects with a negative Phadiatop® test in 1991; ** Among subjects with a positive 
Phadiatop® test in 2002; a In parentheses: 95%-confidence intervals
Table 2
Transition probabilities in different age groups for Phadiatop® in the SAPALDIA
 population (1991–2002).
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1030) or symptoms of hay fever (defined as a self-
reported hay fever for the year of the study or the
year before, N = 942). Table 5 shows that there
was no relevant difference in asthma evolution
between the groups and that the rate of new hay
fever did not statistically differ between the three
groups of subjects with any form of sensitisation. 
Area Total tested Ambrosia positive & Ambrosia positive & Total 
for Ambrosia Artemisia positive Artemisia negative Ambrosia positive**
N %a N % N %a
Basel 778 58 7.5 (5.7–9.5) 16 2.1 (1.2–3.3) 80 10.3 (8.2–12.6)
Wald 1095 48 4.5(3.2–5.8) 14 1.3 (0.7–2.1) 85 7.8 (6.2–9.5)
Lugano 741 39 5.3 (3.8–7.1) 9 1.2 (0.6–2.3) 51 6.9 (5.2–9.0)
Payerne 810 33 4.1 (2.8–5.7) 7 0.9 (0.3–1.8) 47 5.8 (4.3–7.6)
Aarau 949 64 6.8 (5.2–8.5) 10 1.1 (0.5–1.9) 79 8.3 (6.6–10.3)
Geneva 398 25 6.3 (4.1–9.1) 4 1.0 (0.3–2.6) 33 8.3 (5.8–11.4)
Total 4771 267 5.7 (5.0–6.3) 60 1.3 (0.9–1.6) 375 7.9 (7.1–8.7)
* Montana and Davos excluded.
** Numbers exceed the sum of the N’s of the subcategories defined by Artemisia sensitisation status since some subjects who were
 sensitised to Ambrosia had missing or invalid data on Artemisia sensitization.
a Percentages with 95%-confidence intervals.
Table 3
Ambrosia and
Artemisia sensitisa-
tion in the SAPALDIA
areas* in 2002.
New cases of hay fever* No new Total New cases No new asthma Total
hay fever of asthma*
Phadiatop® neg. and 38 690 728 14 703 717
Ambrosia neg. 5.2% (3.7–7.1) 94.8% 77.3% 2.0% (1.1–3.3) 98.0% (69.6%)
Phadiatop® pos. and 28 136 164 15 205 220
Ambrosia neg. 17.1% (11.7–23.7) 82.9% 17.4% 6.8% (3.9–11.0) 93.2% (21.4%)
Phadiatop® neg. and 0 2 2 0 3 3
Ambrosia pos. 0% (0–77.6) 100% 0.2% 0% (0–63.2) 100% (0.3%)
Phadiatop® pos. 13 35 48 7 83 90
and Ambrosia pos. 27.1% (15.3–41.8) 72.9% 5.1% 7.8% (3.2–15.4) 92.2% (8.7%)
Total 79 863 942 36 994 1030
8.4% (6.7–10.3) 91.6% 100% 3.5% (2.5–4.8) 96.5% (100%)
* Absolute frequency and row percentage (with 95% confidence interval in parentheses)
Table 5
Incidence of asthma
and hay fever in dif-
ferent groups of sub-
jects with distinct
sensitisation patterns
at baseline (areas
Lugano and Geneva).
SAPALDIA 2002
Ambrosia Ambrosia positive and Ambrosia positive and Total Ambrosia
negative Artemisia negative Artemisia positive tested
Ambrosia negative 966 (98.6%) 3 (0.3%) 11 (1.1%) 980 (90.6%)
Ambrosia positive and 14 (66.7%) 2 (9.5%) 5 (23.8%) 21 (1.9%)
Artemisia negative
Ambrosia positive and 30 (37.0%) 7 (8.6%) 44 (54.3%) 81 (7.5%)
Artemisia positive
Total Ambrosia tested 1010 (93.3%) 12 (1.1%) 60 (5.5%) 1082 (100%)
Red shaded: positive converters, i.e., subjects having become newly IgE positive (sensitised) between 1991 and 2002
Green shaded: negative converters, i.e., subjects having become IgE negative (lost sensitisation) between 1991 and 2002
Table 4
Development of
 Ambrosia sensitisa-
tion between 1991
and 2002 (Geneva
and Lugano only).
SA
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Discussion 
Sensitisation to Ambrosia pollen has attracted
considerable attention in Switzerland and else-
where in recent years, and several publications
have suggested that Ambrosia may become an im-
portant hazard for asthmatics in Switzerland as in
other affected areas with high plant counts [5],
such as Italy [19]. It has been postulated that 
already an Ambrosia pollen load of more than 
11 pollen/m3 air can lead to allergic symptoms [20].
This pollen amount has been repeatedly exceeded
in Switzerland in recent years in parts of the can-
ton Ticino and almost attained in the Geneva area
[21].
In this study we were not able to confirm 
an increase in Ambrosia sensitisation in the popu-
lations examined. However, observations and 
experience from other countries with a high 
Ambrosia load should prompt us to keep a watch
on this plant [22]. In Switzerland Artemisia is
widespread and sensitisation to its pollen is cur-
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rently more prevalent and more widespread than
to Ambrosia.
However, the potential cross-reactivity be-
tween allergens of these two pollens may render
patients initially sensitised to Artemisia pollen
sensitive to Ambrosia as well. Unfortunately we
are unable to distinguish between the two sensiti-
sations, but our results allow the speculative
 conclusion that the observed sensitisation to Am-
brosia in Switzerland may so far have in large part
been due to primary sensitisation to Artemisia
leading by cross-reactivity to sensitisation against
Ambrosia.
For this reason future preventive campaigns
may need to warn allergic individuals against both
Ambrosia and Artemisia. Patients with inhalant
 allergies should be aware that sensitisation to
Artemisia may at a later stage develop into an al-
lergy against Ambrosia, and that therefore expo-
sure to Artemisia should also be avoided. 
In general, no increase in sensitisation to res-
piratory allergens could be observed in our study
populations or in those with potential exposure to
Artemisia pollen. The apparent decrease in sensi-
tisation is partially explained by the increasing age
of the population studied and the concomitant in-
creased probability of losing sensitisation. This is
consistent with the findings of the ECRHS study,
which suggest that the widely observed upward
trends in sensitisation rates across Europe may es-
sentially reflect a cohort phenomenon [23]. In this
regard further observations are needed. 
In any case, our results do not support the no-
tion that Ambrosia plants and pollen are already
an important cause of inhalant allergies in
Switzerland at present and therefore do not yet
represent an important public health issue. Our
results documenting low Ambrosia sensitisation
rates in 1991 and also in 2002 further suggest that
the feared rise in sensitisation to Ambrosia has
not yet occurred. Campaigns to eliminate Am-
brosia wherever possible are nevertheless manda-
tory, to avoid a further spread of Ambrosia which
could involve very severe and widespread allergies
as observed in Hungary, Italy or France in recent
decades.
In summary, our results document low Am-
brosia sensitisation rates in 1991 and in 2002,
even in areas with a significant Ambrosia pollen
load, strongly suggesting that the feared rise in
sensitisation to Ambrosia has not yet taken place.
To the best of our knowledge the situation has not
dramatically changed in the meantime: thus the
situation provides a not-to-be-missed window of
opportunity for the introduction of effective pre-
ventive measures.
We would like to express our gratitude to the partici -
pants in the two SAPALDIA studies, to the field workers
who have collected the data and biological samples for
the present analysis and in particular to Ms. Irène Cuhat
Stark and Ms. Suzanne Marti-Wyss of the Allergology
Laboratory, Zurich University Hospital Dept. of Derma-
tology, and to Ms. Marie-Claire Weber-Lurati of the
Zurich University Hospital Immunology Clinic for their
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total and specific IgE in both instances.
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